Joseph Gathe is an Infectious Disease physician. ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4900 Fannin St
Houston, TX 770045706
Telephone
713-526-9821Registry record last updated 16 Dec 2008.
Clinical trials
- Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19
Sponsor: Hope Biosciences Research Foundation
- A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects
Sponsor: Therapeutic Concepts
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
42 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year2025128 payments$103,837openpaymentsdata.cms.gov ↗
- EMD Serono, Inc.Program year202537 payments$39,932openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202510 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
46.5%Protease Inhibitor17.2%Prezcobix38%Symtuza26%Ritonavir15%Darunavir9%Lopinavir-Ritonavir4%Atazanavir Sulfate4%Evotaz2%Prezista1%Part D<11 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor7.1%Descovy38%Triumeq31%Emtricitabine-Tenofovir Disop19%Abacavir-Lamivudine8%Emtricitabine2%Zidovudine2%Part D<11 patients+ 23 more classes in this area
Cardiovascular
14.7%Angiotensin receptor blocker (ARB)3%Losartan-Hydrochlorothiazide66%Losartan Potassium29%Olmesartan Medoxomil5%Part D<11 patientsCalcium channel blocker2.9%Amlodipine Besylate96%Nifedipine Er5%Part D<11 patients+ 11 more classes in this area
Nervous system
11.6%SSRI2.3%Trazodone Hcl42%Escitalopram Oxalate23%Sertraline Hcl17%Citalopram Hbr12%Paroxetine Hcl6%Part D<11 patientsGabapentinoids1.6%Gabapentin61%Pregabalin39%Part D≥22 patients+ 15 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”